INDIA MARKET LENS

Anthem Biosciences Limited (ANTHEM): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Anthem Biosciences Limited, explained in plain English.

  • Anthem Biosciences Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • ANTHEM closed at ₹951.05 on 20 November 2026.
  • Over the past year the shares are up 49.7%, trading between ₹579.15 and ₹989.10.
  • Reported fundamentals show return on equity of 20.35%, a net margin of 29.95%, debt to equity of 1.25.
  • Our Pulse grade checklist scores it A (86/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 28.89% with a maximum drawdown of -16.4% and a beta of 0.55 against NIFTY 50.

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 20 Nov 2026. Closed — weekend.

Anthem Biosciences Limited (ANTHEM)

₹915.55

▼ 8.7 (-0.94%)

Price & volume

ANTHEM price chart, 1Y range. 252 points from 2025-11-20 to 2026-11-18. Opens at 647.45, closes at 915.55, ranging between 592.4 and 958.15.600700800900Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 5/5
✓ Above 50-day avg✓ Above 200-day avgRSI 57.4 · healthyMACD positiveBollinger %B 65ADX 30.8 · strong trend

1M

+11.36%

3M

+2.75%

6M

+16.06%

1Y

+38.81%

Where it sits in its 52-week range

88%
₹592.4₹958.15

Below 52-week high

4.4%

54.5% above the low

Momentum read

Strong

5/5 checks passed

52-wk high

₹958.15

52-wk low

₹592.4

Market cap

₹52,084 Cr

P/E (trailing)

85.4

Dividend yield

—

ROE

20.35%

Profit margin

29.95%

Revenue growth

8%

Price / Book

15.88

Debt / Equity

1.25

EPS (TTM)

10.82

Book value

₹58.18

Beta

0.54

Pulse grade: A, 86 out of 100

Momentum

A
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✓Positive 3-month return

Growth

C
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

A
  • ✓Return on equity above Pharma & Healthcare median (14.64%)
  • ✓Return on equity above 12%
  • ✓Profit margin above Pharma & Healthcare median (13.82%)

Safety

A
  • ✓Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹594 crore · net profit ₹211 crore · margin 35.5%

6110Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,871+0.05%-6.50%
DRREDDY1,388.4+0.76%+0.03%
CIPLA1,428.2+2.90%-6.99%
DIVISLAB11,135.5-0.13%-3.72%
APOLLOHOSP8,722.5-0.55%-3.82%
LUPIN1,961.1+0.57%-22.02%

ANTHEM headlines

No ANTHEM stories right now.

ANTHEM filings & announcements

Reading the exchange…

ANTHEM, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

28.84%

Sharpe ratio

1.13

Sortino ratio

1.86

Max drawdown

-16.4%

Daily VaR (95%)

-2.56%

CAGR (1Y)

41.6%

Return skew

0.55

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.